我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
10
0 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
已完成
7
70.0%
终止
2
20.0%
Unknown
1
10.0%
暂无批准数据
- Life Biosciences has appointed industry veteran David Guyer, M.D., to its Board of Directors as the company prepares to initiate human trials for its lead program ER-100 in the first quarter of 2026. - Dr. Guyer brings over 30 years of drug development experience, including developing the first anti-VEGF drug for macular degeneration and overseeing the sale of EyeBio to Merck in July 2024. - The company's proprietary Partial Epigenetic Reprogramming platform utilizes three transcription factors to restore older cells to a younger state, targeting age-related diseases at the epigenetic level. - ER-100 is being developed for optic neuropathies including glaucoma and non-arteritic anterior ischemic optic neuropathy, representing a novel approach to treating age-related eye diseases.
